Dr. McGill graduated from Michigan State University College of Human Medicine, then completed her internship, residency and was chief resident in internal medicine at William Beaumont Hospital in Royal Oak Michigan. After her fellowship in Endocrinology at Washington University, she joined the faculty in 1987. She has been an active clinical researcher in diabetes for over 25 years, and continues to test new therapies for diabetes and novel approaches to type 1 and type 2 diabetes. Dr. McGill has served on steering and safety committees for multi-centered clinical trials, including RENAAL, TREAT, FOCAL, KEEP, SUN and PERL studies in diabetic nephropathy; and currently serves on planning committees and data safety monitoring boards for a number of ongoing national and international clinical trials. She is a past member of the board of directors for the American Association of Clinical Endocrinologists, and the AACE Diabetes Scientific Committee that recently published updated guidelines for the care of persons with type 2 diabetes.
Dr. McGill is the former director of the Fellowship in Endocrinology, Diabetes and Metabolism and has a busy practice at the Center for Advanced Medicine treating patients with diabetes, thyroid disease and other endocrine problems.
Diabetes affects 12% of the US population, and has devastating long term effects that both shorten life and greatly alter the quality of life. The treatment of diabetes has improved with the advent of newer therapies that target multiple metabolic pathways. Nonetheless, patients often face severe consequences of vision loss, end stage kidney disease, cardiovascular disease and are at increased risk for depression. Dr. McGill and her staff, along with colleagues in the Division of Endocrinology, Metabolism and Lipid Research, conduct numerous clinical trials in type 1 diabetes, type 2 diabetes, atypical diabetes, hyperlipidemia and vitamin D deficiency. The recently completed Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE study), compared four treatments as second line therapy for diabetes. Additionally, Dr. McGill has tested innovative insulin pumps and continuous glucose monitors, which have greatly impacted the safety and efficacy of insulin delivery. The clinical research staff in the Division of Endocrinology, Metabolism and Lipid Research includes two nurses, an administrator, and a medical assistant who have years of experience doing both investigator-initiated and multi-centered clinical trials.
Dr. McGill has been an invited speaker for local, regional, national and international meetings and symposia.
Awards and Honors
Best Doctor, 1998-2013
America’s Top Doctor 2007-2013
Named Best Doctor in Women’s Health, 2008
Fellow, American Association of Clinical Endocrinologists, 2002
Distinguished Clinician Award, Washington University School of Medicine, 2014
Alpha Omega Alpha Honor Society, Michigan State University College of Human Medicine, 2016
Resident/Fellow Alumni Achievement Award, Washington University Medical Center Alumni Associationm 2917
Excellence in Teaching Award, Washington University Division of Endocrinology, Metabolism and Lipid Research, 2020
Fellow, Americal College of Physicians, 2020
Outstanding Physician Clinician in Diabetes Award, American Diabetes Association, 2022
Samuel EIchold II Memorial Award for Contributions in Diabetes, American College of Physicians, 2023